Galderma (SWX:GALD) today announced that the European Commission has approved Nemluvio for both moderate-to-severe atopic dermatitis and prurigo nodularis in the European Union (EU). Nemluvio is ...

showing that Nemluvio has the potential to address the significant unmet needs of patients with atopic dermatitis and prurigo nodularis 1-3 There is a need for new treatment options for atopic ...

Prurigo nodularis is a chronic skin condition that causes intensely itchy bumps. These hard lumps, called nodules, often appear on areas you can easily scratch, like your arms, legs, and upper back.

Galderma’s nemolizumab has been shown to improve the core signs and symptoms of prurigo nodularis, according to phase 3 results published in JAMA Dermatology. The 24-week OLYMPIA 1 trial evaluated the ...

Prurigo Nodularis, characterized by intensely itchy nodules of the skin, significantly impacts patients' quality of life. The introduction of Galderma's innovative therapy offers new hope for ...

Prurigo nodularis is an extremely itchy skin condition. It causes a rash that often includes hard lumps called nodules. You might also hear it called nodular prurigo. Doctors don’t know exactly ...

Patients may self-inject Nemluvio after receiving training on SC injection technique. The Food and Drug Administration (FDA) has approved Nemluvio ® (nemolizumab-ilto) for the treatment of adults ...

The U.S. Food and Drug Administration has approved Galderma's Nemluvio (nemolizumab) for adult patients living with prurigo nodularis. Nemluvio, administered as a prefilled pen for subcutaneous ...

“The U.S. FDA’s rapid approval of Nemluvio in prurigo nodularis is a first step in achieving its blockbuster platform potential and reinforces our leadership in therapeutic dermatolog ...

It was based on positive results from the phase 3 Olympia 1 (NCT04501679) and 2 (NCT04501666) trials, which evaluated the safety and efficacy of nemolizumab administered subcutaneously every 4 ...